Severance Hospital
| Corea del Sud | Turchia | Austria | |
| CyberKnife | da $11,500 | da $4,750 | da $50,000 |
| Bisturi Nanotecnologico | da $17,500 | da $9,500 | da $25,000 |
| Terapia con Actinio-225 | - | da $22,955 | da $55,000 |
| Enucleazione di tumore sul pancreas | - | da $10,000 | - |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Tumori neuroendocrini del pancreas. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Tumori neuroendocrini del pancreas e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Tumori neuroendocrini del pancreas.
Il medico è una figura di spicco nel campo della chirurgia, ricoprendo ruoli di leadership come Direttore del Comitato di Formazione e Educazione presso la Società Chirurgica Coreana e Direttore del Comitato di Tecnologia dell'Informazione presso la Società Coreana di Coloproctologia. Il medico è anche Direttore del Consiglio degli Affari Chirurgici presso la Società Coreana di Gastroenterologia e Vicepresidente dell'Associazione Coreana dei Chirurghi Robotici.<\/p>
Con un solido background educativo dall'Università della Corea, il medico ha dimostrato competenza chirurgica a livello internazionale, inclusi la Facoltà di Medicina dell'Università Cinese di Hong Kong e l'Ospedale Tan Tock Seng a Singapore.<\/p>
Top medical centers for pancreatic neuroendocrine tumor treatment in South Korea include Severance Hospital and Korea University Anam Hospital. These JCI-accredited facilities offer advanced pancreatic enucleation and multidisciplinary care. Most centers utilize robotic surgery and advanced imaging to ensure precise tumor removal and preservation of organ function.
Bookimed Expert Insight: Korea University Anam Hospital is a strategic choice for high-precision cases. They pioneered robotic surgery methods and emphasize bloodless procedures. This approach significantly reduces infection risks and shortens recovery time for pancreatic patients. Their volume of 1.3 million annual patients suggests deep experience in managing complex oncology cases.
Patient Consensus: Patients note it is vital to secure a pathology second opinion for Ki-67 grading. High-volume university hospitals in Seoul are preferred for their specialized multidisciplinary tumor boards.
Treatment for pancreatic neuroendocrine tumors in South Korea involves multidisciplinary care at JCI-accredited university hospitals. Options include da Vinci robotic surgery, peptide receptor radionuclide therapy (PRRT), and targeted drug treatments. Specialists focus on tumor grade and Ki-67 index to determine precise surgical or systemic protocols.
Bookimed Expert Insight: Korea University Anam Hospital utilizes bloodless surgery protocols to minimize infection risks during complex tumor resections. This is particularly valuable for pNET patients undergoing major pancreatic surgery. Their multidisciplinary teams integrate pathology and oncology to refine treatment plans after reviewing Ki-67 indexes.
Patient Consensus: Patients note that getting a detailed pathology report with the Ki-67 index is essential before surgery. Many emphasize that university hospitals coordinate specialist input faster than smaller clinics.
South Korean outcomes for pancreatic neuroendocrine tumors are excellent. Five-year survival rates exceed 80% for local cohorts. Large JCI-accredited tertiary centers achieve 10-year survival rates near 90% for small nonfunctioning tumors. These results match or exceed international standards found in Western Europe and North America.
Bookimed Expert Insight: Patient volume is a reliable indicator of outcomes in Seoul. Severance Hospital alone manages 1.6 million outpatients annually. Our data suggests this massive scale allows surgeons to specialize specifically in rare neuroendocrine variants rather than general pancreatic care. This volume-driven expertise likely contributes to Korea's high 93% recurrence-free survival rates.
Patient Consensus: Patients emphasize finding the highest-volume specialist rather than just a reputable hospital. They frequently praise the speed of Korean centers where workups and surgery scheduling happen much faster than in Western systems.
South Korean hospitals offer robot-assisted pancreatic surgery for pancreatic neuroendocrine tumors (pNETs). Specialized oncology centers in Seoul utilize the Da Vinci system and the domestic Revo-i platform. These systems allow for precise tumor removal, including procedures like pancreaticoduodenectomy and distal pancreatectomy.
Bookimed Expert Insight: Korea University Anam Hospital stands out for its high-volume robotic expertise. This clinic reports serving over 1,300,000 patients annually. Their surgeons specifically focus on robotic excellence in cancer surgery. This high volume often correlates with better technical precision in complex pancreatic resections.
Patient Consensus: Patients emphasize that the surgeon's specific experience with pancreatic cases is more important than the robot itself. They note that while robotic surgery leaves smaller scars, the recovery remains serious due to potential drainage requirements.
Management of advanced pancreatic neuroendocrine tumors in Korea involves a multidisciplinary approach. Specialized oncology centers utilize systemic therapies, such as everolimus and sunitinib, alongside targeted radionuclides. JCI-accredited facilities offer localized treatments like CyberKnife stereotactic radiosurgery and NanoKnife irreversible electroporation for complex metastases.
Bookimed Expert Insight: Korea is a high-volume hub. Centers like Severance Hospital serve 4 million patients yearly. This massive patient volume allows Korean specialists to manage rare cases including complex pNETs with high proficiency. Their expertise is consistently recognized in Newsweek's World's Best Hospitals rankings.
Patient Consensus: Patients emphasize the need for detailed pathology, specifically checking Ki-67 levels and receptor status. Confirming somatostatin-receptor positivity is a vital step before starting advanced radionuclide therapies.
Major Korean tertiary centers including Asan Medical Center, Seoul National University Hospital, and Samsung Medical Center provide Lutetium-177 DOTATATE PRRT for pancreatic neuroendocrine tumors. These JCI-accredited facilities utilize nuclear medicine departments to deliver targeted radiation. Treatment typically follows progression on somatostatin analogs.
Bookimed Expert Insight: Korea University Anam Hospital and Severance Hospital serve over 1,300,000 and 1,600,000 patients annually. This massive patient volume allows these centers to maintain dedicated multidisciplinary teams for rare conditions like pNETs. JCI-accredited hubs often centralize nuclear medicine, so treatment availability is highest in Seoul-based university hospitals.
Patient Consensus: Patients note it is important to confirm the nuclear medicine department actually performs PRRT dosing. Some centers provide the diagnostic DOTATATE scans but refer the actual treatment to larger national hubs.